TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05514002

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok Quadrivalent
Description: Intramuscular
Study: NCT05780437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
Study: NCT05181852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015, dose 1
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015, dose 2
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Comparator
Study: NCT05780437

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT06254079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video based education
Description: The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
Study: NCT06546241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celebrandome
Description: This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
Study: NCT05810246

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)
Description: 68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT.
Study: NCT06154980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Ultrasound TLIP
Description: TLIP will be performed in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative TLIP
Description: TLIP will be performed intraoperatively with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks under direct surgical visualization.
Study: NCT06356662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: take tenofovir disoproxil fumarate 300mg/d
Study: NCT05826925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
Study: NCT06356662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: take tenofovir disoproxil fumarate 300mg/d
Study: NCT05113251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: administered by intravenous infusion
Study: NCT04251182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg T3D-959
Description: Oral administration once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg T3D-959
Description: Oral administration once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg T3D-959
Description: Oral administration once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration once daily in the morning
Study: NCT05945394

Intervention type: OTHER
Intervention: No intervention
Description: This is an obvertional study, and there is no intervention.
Study: NCT05779150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CeraVe® Moisturising Cream
Description: CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Cream
Description: placebo cream
Study: NCT05312567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-101
Description: daily oral tablet administration (b.i.d.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-101
Description: daily oral tablet administration (b.i.d.)
Study: NCT05877950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy
Description: Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based speech therapy
Description: Participants will receive treatment maintaining the same frequency as the intervention group.
Study: NCT05994144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIDEO OBSERVED THERAPY
Description: Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
Study: NCT04356326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
Study: NCT05113251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: administered by intravenous infusion
Study: NCT06491251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Subinguinal microscopic varicocelectomy
Description: Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
Study: NCT04895410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion
Study: NCT05104528

Intervention type: DEVICE
Group type: OTHER
Intervention: OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3
Description: Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fujifilm Sonosite M-Turbo C Ultrasound system
Description: A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
Study: NCT05113251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: administered by intravenous infusion
Study: NCT05654870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: Oral treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching valbenazine
Study: NCT04915820

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: intravenous iron carboxymaltose
Study: NCT04984226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
Study: NCT04895410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lemzoparlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection
Study: NCT05256108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 40 mg
Description: Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 600 mg
Description: Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 1000 µg
Description: Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
Study: NCT05655676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-NY008
Description: Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
Study: NCT01055925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing
Study: NCT05362396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training with Powerbreath IMT device.
Description: Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
Study: NCT04895410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or IV infusion/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous (SC) injection
Study: NCT05235594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor
Description: The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
Study: NCT04893902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medit intra oral scanner
Description: ear scanning with intra oral scanner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medit intra oral scanner
Description: ear scanning with intra oral scanner

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medit intra oral scanner
Description: ear scanning with intra oral scanner
Study: NCT06575998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pro-active identification
Description: Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
Study: NCT04968015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine-Venetoclax Association
Description: Consolidation treatment with cytarabine + venetoclax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine-Idarubicin Association
Description: Consolidation treatment with cytarabine + idarubicin
Study: NCT05928858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premixed Bio-ceramic MTA
Description: Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration